

# Paul Delmar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3399016/publications.pdf>

Version: 2024-02-01

7  
papers

310  
citations

1684188  
5  
h-index

1720034  
7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

676  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. <i>Angiogenesis</i> , 2014, 17, 909-920.	7.2	40
2	Genetic markers of bevacizumab-induced hypertension. <i>Angiogenesis</i> , 2014, 17, 685-94.	7.2	24
3	Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2013, 35, 809-818.	2.0	5
4	An industry statistician's perspective on PHC drug development. <i>Contemporary Clinical Trials</i> , 2013, 36, 624-635.	1.8	5
5	VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AVITA and AVOREN randomised trials. <i>Lancet Oncology</i> , The, 2012, 13, 724-733.	10.7	174
6	A statistician's perspective on biomarkers in drug development. <i>Pharmaceutical Statistics</i> , 2011, 10, 494-507.	1.3	40
7	Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2517-2525.	4.1	22